Pfizer's Q2 2026 results revealed 1% operational revenue growth and a 12% earnings per share beat, driven by strong non-COVID sales and a robust product pipeline. The company's Cost Realignment Program is expected to save $7.2 billion by 2026 and an additional $2.5 billion through 2029, boosting future profitability. Despite risks from patent expirations, Pfizer offers an attractive valuation, a nearly 6.5% dividend yield, and a projected total return of 30% over the next 12-16 months. This positions Pfizer as a promising investment opportunity as it recovers from post-COVID challenges.
Pfizer is moving its business focus away from COVID-19 products to its broader non-COVID portfolio, which grew 5% in Q2 2026. The company beat earnings estimates by 12% and raised its revenue guidance by $500 million, signaling strong financial healt...
Revolution Medicines closed at $205.55 on August 11, 2026, reaching a $44.1 billion market cap driven by its promising RAS-targeting oncology pipeline. The company has no current product revenue but shows strong clinical results, especially with dara...
Investors seeking reliable income and growth should consider five S&P 500 stocks with dividend yields above 6%, including Altria, Pfizer, VICI Properties, General Mills, and Verizon. These companies have long histories, stable dividends, and strong m...
